The following information is obtained from various newswires,
published medical journal articles, and medical conference presentations.
Company: Knoll Pharmaceutical
Approval Status: Approved May 1996
Treatment for: hypertension
General Information
Mavik is an angiotensin converting enzyme (ACE) inhibitor indicated for the treatment of hypertension when used alone or in combination with other antihypertensive medication, such as hydrochlorothiazide. Knoll Pharmaceutical Company expects to make Mavik available by prescription in one mg, two mg, and four mg dosage strengths. In Afro-American subjects, the minimal effective daily dose is two mg (versus one mg in Caucasians).
Clinical Results
In clinical studies, Mavik was shown to provide excellent 24-hour blood pressure control when taken once daily.
Side Effects
Mavik was well tolerated in clinical trials. The most common side effects were cough (1.9%), dizziness (1.3%), and diarrhea (1.0%). Headache and fatigue occurred in less than 1% of patients, but were reported more often on placebo. Mavik is contraindicated in subjects who are hypersensitive to the product. Angiodema has been reported in subjects receiving ACE inhibitors.
Additional Information
The clinical significance of tissue ACE inhibition has not been established.
